β3-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility

Journal of Clinical Investigation

Volumn 106, Issue 5, 2000, Pages 697-703

  Varghese, Paul ^a   Harrison, Robert W ^a   Lofthouse, Robert A ^a   Georgakopoulos, Dimitrios ^a   Berkowitz, Dan E ^a   Hare, Joshua M ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; ISOPRENALINE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; HEART MUSCLE CONTRACTILITY; INOTROPISM; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0033823132     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI9323     Document Type: Article

References (57)

1. Balligand, J.-L., Kelly, R.A., Marsden, P.A., Smith, T.W., and Michel, T. 1993. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl. Acad. Sci. USA. 90:347-351.
2. Hare, J.M., and Colucci, W.S. 1995. Role of nitric oxide in the regulation ot myocardial function. Prog. Cardiovasc. Dis. 38:155-166.
3. Hare, J.M., Loh, E., Creager, M.A., and Colucci, W.S. 1995. Nitric oxide inhibits the contractile response to β-adrenergic stimulation in humans with left ventricular dysfunction. Circulation. 92:2198-2203.
4. Hare, J.M., et al. 2000. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Cir. Res. 86:1085-1092.
5. Gyurko, R., Kuhlencordt, P., Fishman, M.C., and Huang, P.L. 2000. Modulation of mouse cardiac function in vivo by eNOS and ANP. Am J. Physiol. Heart Circ. Physiol. 278:H971-H981.
6. DeBelder, A.J., et al. 1493. Nitric oxide synthase activities in human myocardium. Lancet. 341:84-85.
7. Haywood, G.A., et al. 1996. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 93:1087-1094.
8. Balligand, J.-L., et al. 1995. Induction of NO synrhase in rat cardiac microvascular endothelial cells by 1L-1β and IFN-γ. Am. J. Physiol. 268:H1293-H1303.
9. Chorinchath, B.B., Kong, L.-Y., Mao, L., and McCallum, L. 1996. Age-associated differences in TNF-α and nitric oxide production in endotoxic mice. J Immunol. 156:1525-1530.
10. Zieman, S.J., Gerstenblith, G., Ricker, K.M., Vandegaer, K., and Hare J.M. 1999. Increased nitric oxide/cGMP signaling enhances diastolic relaxation in aged rat myocardium, Circulation. 100:1483. (Abstr.)
11. Kanai, A.J., et al. 1997. β-Adrenergic regulation of constitutive nitnc oxide synthase m cardiac myocytes. Am. J. Physiol. 273:C1371-C1377.
12. 3adrenoreceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J. Clin. Invest. 102:1377-1384.
13. 3adrenoceptor in the human heart. J. Clin. Invest. 98:556-562.
14. Kaumann, A. J. 1997. Four β-adrenocepror subtypes in the mammalian heart. Trends Pharmacol. Sci. 18:70-76.
15. Bond, R.A., and Clarke, D.E. 1998. Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the α-and β-subtypes. Br. J. Pharmacol. 95:723-734.
16. 3-drenoceptor: the search for a physiologic function. Trend Pharmacol. Sci. 15:3-7.
17. 3-adrenoceptor? Trends Phar. macol. Sci. 10:316-320.
18. 3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. J. Biol. Chem. 272:17686-17693.
19. 3-adrenoreceptor agonists. J. Pharmacol. Exp. Ther. 290:687-693.
20. 3-adrenergic receptors under the control of human gene regularory elements. Diabetes. 47:1464-1471.
21. Fletcher, D.S., et al. 1998. Beta-3 adrenorgic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor. J. Pharmacol. Exp. Ther. 287:720-724.
22. 3-adrenergic receptor gene. J. Biol. Chem. 270:29483-29492
23. Huang, P.L., et al. 1995. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 377:239-242.
24. Georgakopoulos, D., et al. 1999, The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat. Med. 5:327-330.
25. Baan, J., et al. 1984. Continuous measurement of left ventricular volume in humans and animals by conductance catheter. Circulation. 70:812-823.
26. Kass, D.A., Yamazaki, T., Burkhoff, D., Maughan, W.L., and Sagawa, K. 1986. Determination of left ventricular end-systolic pressure-volume relationships by the conductance (volume) catheter technique. Circulation. 73:586-595.
27. Kelly, R.P., et al. 1992. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 86:513-521.
28. Kass, D.A. 1997. Myocardial mechanics. In Heart failure. P. Poole-Wilson, W. Colucci, B. Massie, K. Chatterjee, and A. Coats, editors. Churchill Livingstone. New York, New York. USA. 87-108.
29. Kass, D.A., et al. 1987. Comparative influence of load versus motropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressures-volume relationships. Circulation. 76:1421-1436.
30. Little, W.C., et al. 1989. Comparison of measures of left ventricular contractile performance derived from pressure-volume loops in conscious dogs. Circulation. 80:1378-1387.
31. Rahko, P.S. 1994. Comparative efficacy of three indexes of left ventricular performance derived from pressure-volume loops in heart failure induced by tachypacing J. Am. Coll. Cardiol. 23:209-218.
32. Mirsky, I., Tajimi, T , and Peterson, K.L. 1999. The development of the entire end-systolic pressure-volume and ejection fraction-afterload relations: a new concept of systolic myocardial stiffness. Circulation. 76:343-356.
33. Gilbert, J.C., and Glantz, S.A. 1989. Determinants of left ventricular filling and of the diastolic pressure-volume relation Circ. Res. 64:827-852.
34. Han, J., Richter, B., Li,Z., Kravchenko, V., and Ulevitch, R.J. 1995 Molecular cloning of human p38 MAP kinase. Biochim. Biophys. Acta. 1265:224-227
35. Stein, B., et al. 1997. p38-2 a novel mitogen-activated protein kinase with distinct properties J. Biol. Chem. 272:19509-19517.
36. Nahmias, C., et al. 1991. Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO 10:3721-3727.
37. Berkowitz D.E., et al. 1998. Endotoxin-induced alteration in the expression of leptin and beta3-adrenergic receptor in adipose tissue. Am J. Physiol. 274:E992-E997.
38. Michel, T., and Feron, O. 1997. Nitric oxide synthases: which, where, how and why? J. Clin. Invest. 100:2146-2152.
39. Dzimiri, N. 1999. Regulation of beta-adrenoceptor signaling in cardiac function and disease. Pharmacol. Rev. 51:465-501.
40. Hare, J.M., and Stamler, J.S. 1999. NOS: modulator, not mediator of cardiac performance. Nat. Med. 5:273-274.
41. Hare, J.M., et al. 1995. Role of nitric oxide in parasympathetic modulation or β-adrenergic myocardial contractility in normal dogs. J. Clin. Invest. 95:360-366.
42. Hare, J.M., et al. 1998. Pertussis toxin-sensitive G proteins influence nitric oxide synthase III activity and protein levels in rat heart. J. Clin. Invest. 101:1424-1431
43. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. USA. 88:1197-1201.
44. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activity. J. Biol. Chem. 268:26286-26295.
45. Shah, A.M., Lewis. M.J., and Henderson, A.H. 1991. Effects of 8-bromo-cyclic GMP on contraction and on inotropic response of ferret cardiac muscle. J. Mol. Cell. Cardiol. 23:55-64.
46. 2+ in intact cardiac myocytes. Circ. Res. 74:970-978.
47. Ji, G.J., et al. 1999 Regulation of the 1-type C2+ channel during cardiomyogenesis: switch from NO ro adenylyl cyclase-mediated inhibition. FASEB J. 13:313-324.
48. Gross, W.L., et al. 1996 Nitric oxide inhibits cteatine kinase and regulates rat heart contractile reserve. Proc. Natl. Acad. Sci. USA. 93:5604-5609.
49. Campbell, D.L., Stamler, J.S., and Strauss, H.C. 1996 Redox modulation of :-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J. Gen. Physiol. 108:277-293.
50. Paolocci, N., et al. 2000. cGMP independent inotropic effect of nitric oxide and peroxynitirite donors: potential role for S-nitrosylation Am. J. Physiol. In Press.
51. 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J. Pharmacol. Exp. Ther. 278:1435-1443.
52. Moniotte, S., et al. 1999. The altered response to β adrenergic stimulation in failing hearts is associated with an upregulation of the β3 adrenoceptor and its coupled Gi-protein, Circulation. 100:1507. (Abstr.)
53. 3-adrenergic activation-induced enhanced cardiac depression in heart failure: assessment by left ventricular pressure-volume analysis. Circulation 100:1552. (Abstr.)
54. Brodde, O.E., 1993. Beta-adrenoceptors in cardiac disease. Pharmacol. Ther. 60:405-430.
55. Liggett, S.B., Freedman, N.J., Schwinn, D.A., and Lefkowitz, R.J. 1993. Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor. Proc. Natl. Acad. Sci. USA. 90:3665-3669.
56. Thomas, R.F., Holt, B.D., Schiwnn, D.A., and Liggett, S.B. 1992. Longterm agonist exposure induces upregulation of beta3-adrenergic receptor expression via multiple cAMP response elements. Proc. Natl. Acad. Sci. USA. 89:4490-4494.
57. Murphy, A.M., et al. 2000. Transgenic mouse model of stunned myocardium. Science. 287:488-491.